Are Analysts Bearish Concordia International Corp. (NASDAQ:CXRX) After Last Week?

March 14, 2018 - By Marguerite Chambers

 Are Analysts Bearish Concordia International Corp. (NASDAQ:CXRX) After Last Week?

Concordia International Corp. (NASDAQ:CXRX) Ratings Coverage

Among 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Concordia Healthcare Corp. had 20 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was initiated by IBC on Monday, November 30 with “Sector Perform”. The firm has “Neutral” rating by Goldman Sachs given on Monday, June 6. Scotia Capital maintained the stock with “Sector Outperform” rating in Friday, October 16 report. The firm has “Hold” rating given on Thursday, August 4 by TD Securities. The stock of Concordia International Corp. (NASDAQ:CXRX) has “Sector Outperform” rating given on Tuesday, September 29 by Scotia Capital. TD Securities downgraded Concordia International Corp. (NASDAQ:CXRX) on Wednesday, February 8 to “Reduce” rating. The rating was maintained by Canaccord Genuity with “Sell” on Wednesday, August 9. The company was reinitiated on Thursday, October 1 by RBC Capital Markets. On Monday, August 15 the stock rating was maintained by Goldman Sachs with “Neutral”. The rating was upgraded by Mackie to “Speculative Buy” on Monday, October 19. Below is a list of Concordia International Corp. (NASDAQ:CXRX) latest ratings and price target changes.

The stock increased 0.05% or $0.0003 during the last trading session, reaching $0.5903. About 37,813 shares traded. Concordia International Corp. (NASDAQ:CXRX) has declined 95.85% since March 14, 2017 and is downtrending. It has underperformed by 112.55% the S&P500.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $30.20 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

More notable recent Concordia International Corp. (NASDAQ:CXRX) news were published by: which released: “Concordia International Obtains Court Protection To Facilitate Capital …” on October 25, 2017, also with their article: “Concordia International Corp. Announces Release Date for Fourth Quarter and …” published on February 21, 2018, published: “Concordia International Corp. Comments on CMA Statement of Objections Related …” on November 21, 2017. More interesting news about Concordia International Corp. (NASDAQ:CXRX) were released by: and their article: “Concordia International Corp. Comments on CMA’s Decision to Close its …” published on February 15, 2018 as well as‘s news article titled: “Concordia International Corp. Takes Next Step to Realign Its Capital Structure …” with publication date: October 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.